In our previous work, we systematically analyzed STAT5A expression across 42 cancer types, revealing its dualistic prognostic impact: elevated STAT5A levels were associated with favorable survival outcomes in breast and bladder carcinomas but with a poorer prognosis in hematologic malignancies [5]. This evidence concerns the gene STAT5A and cancer.